Q1 sales hurt by lower US sales, but other regions contributed well. Fine-tuned sales estimates, but we lift our GM assumptions. Ovzon-3 sales to gradually ramp-up in H2e, 10% FCF yield in '25e.
We expect 16% EBITA growth in 2024 from better market & scale. Estimates down on European miss and FX, adj. EBITA -5-8%. Share at 14.3x 2024e EV/EBITA with 15% EBITA CAGR '23-'26e.
Adj. EBITA of SEK 63m, 0% vs. ABGSCe in Q4. FCF was softer because of negative working capital effect. EBITA ests -4-5%; share is trading at 4.7x-2.7x '24e-'26e EV/EBITA.
Good ending to 2023 with strong margin improvements. We lift '24e-'25e EBIT by 9-5% on lower opex. Share is trading at 23x and 15x '24e and '25e EV/EBIT.
Sales and orders grew nicely in Q4, but comps are getting tougher. We stick to ~15% annual growth ahead, EBIT cut 2-4% on lower GM. Several growth drivers ahead, share at 34x 2024e EV/EBIT.
Well positioned to regain growth from AI and cybersecurity. Adj. EBITA +1-3%, EPS +2-4% from completed buybacks. Share at 7.5x 2024e EV/EBITA, 30% below peers.
Higher sales and lower costs behind strong margin expansion. We lift '24e EBIT by 12% on lower opex assumptions. Good outlook for higher margins in '24e, 8x '24e EV/EBIT.
Tough comps in Q4e but tailwinds into 2024e. Cost reductions to yield margin expansion ahead. Share at 7.1x 2024e EV/EBITA, -37% vs . IT re-seller peers.